TuisGNMSF • OTCMKTS
add
Genmab
Vorige sluiting
$194,00
Dagwisseling
$192,95 - $197,31
Jaarwisseling
$190,47 - $323,02
Markkapitalisasie
12,87Â mjd USD
Gemiddelde volume
6,10Â k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
CPH
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (DKK) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 5,54Â mjd | 17,57% |
Bedryfskoste | 3,15Â mjd | 6,78% |
Netto inkomste | 1,27Â mjd | -39,83% |
Netto winsgrens | 22,85 | -48,82% |
Wins per aandeel | 0,29 | -38,43% |
EBITDA | 2,20Â mjd | 26,09% |
Effektiewe belastingkoers | 26,35% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (DKK) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 17,32Â mjd | -37,08% |
Totale bates | 39,66Â mjd | 12,55% |
Totale aanspreeklikheid | 7,74Â mjd | 87,54% |
Totale ekwiteit | 31,92 mjd | — |
Uitstaande aandele | 63,51 m | — |
Prys om te bespreek | 0,39 | — |
Opbrengs op bates | 13,53% | — |
Opbrengs op kapitaal | 16,33% | — |
Kontantvloei
Netto kontantverandering
| (DKK) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 1,27Â mjd | -39,83% |
Kontant van bedrywe | 2,03Â mjd | -0,20% |
Kontant van beleggings | 224,00Â m | -77,78% |
Kontant van finansiering | -276,00Â m | -1Â 480,00% |
Netto kontantverandering | 2,01Â mjd | -40,84% |
Beskikbare kontantvloei | 1,42Â mjd | 9,09% |
Meer oor
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US. Wikipedia
Gestig
1999
Webwerf
Werknemers
2Â 635
